Decision analysis modelling of costs and outcomes following cefepime monotherapy in Canada

Michael Halpern, Ruth E. Brown, Martine Drolet, Sonja V. Sorensen, Lionel A. Mandell

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: To evaluate the comparative cost of treatment and intermediate outcomes (percentage resistant organisms, days in hospital, etc) among cefepime and alternative parenteral antibiotics used for empiric monotherapy. Design: Decision analysis model, based on published literature, clinical trial results and information from infectious disease clinicians. Setting: A Canadian tertiary care hospital. Intervention: Comparison of cefepime, ceftazidime, ceftriaxone, cefotaxime and ciprofloxacin in the treatment of lower respiratory tract infections, urinary tract infections, skin/soft tissue infections, septicemia and febrile neutropenia. Main results: Cefepime treatment results in the lowest average cost per patient when used as initial empiric therapy for lower respiratory tract infections and for skin/soft tissue infections. Cefepime therapy is among the lowest cost treatments for the other infectious disease conditions and has the lowest cost for a weighted 'average' condition. Sensitivity analysis indicates that model results are most sensitive to duration of hospitalization. Conclusions: Initial empiric monotherapy with cefepime for serious infectious disease conditions may result in cost savings compared with alternative parenteral agents.

Original languageEnglish (US)
Pages (from-to)19-27
Number of pages9
JournalCanadian Journal of Infectious Diseases
Volume8
Issue number1
StatePublished - 1997
Externally publishedYes

Fingerprint

Decision Support Techniques
Canada
Costs and Cost Analysis
Communicable Diseases
Soft Tissue Infections
Respiratory Tract Infections
Febrile Neutropenia
Skin
Ceftazidime
Cefotaxime
Ceftriaxone
Cost Savings
Tertiary Healthcare
Therapeutics
Ciprofloxacin
Tertiary Care Centers
Urinary Tract Infections
Health Care Costs
Sepsis
Hospitalization

Keywords

  • antibiotics
  • cefepime
  • costs
  • decision analysis
  • economic models

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Decision analysis modelling of costs and outcomes following cefepime monotherapy in Canada. / Halpern, Michael; Brown, Ruth E.; Drolet, Martine; Sorensen, Sonja V.; Mandell, Lionel A.

In: Canadian Journal of Infectious Diseases, Vol. 8, No. 1, 1997, p. 19-27.

Research output: Contribution to journalArticle

Halpern, Michael ; Brown, Ruth E. ; Drolet, Martine ; Sorensen, Sonja V. ; Mandell, Lionel A. / Decision analysis modelling of costs and outcomes following cefepime monotherapy in Canada. In: Canadian Journal of Infectious Diseases. 1997 ; Vol. 8, No. 1. pp. 19-27.
@article{714166ed48974a06b215aae0b0d4db3b,
title = "Decision analysis modelling of costs and outcomes following cefepime monotherapy in Canada",
abstract = "Objective: To evaluate the comparative cost of treatment and intermediate outcomes (percentage resistant organisms, days in hospital, etc) among cefepime and alternative parenteral antibiotics used for empiric monotherapy. Design: Decision analysis model, based on published literature, clinical trial results and information from infectious disease clinicians. Setting: A Canadian tertiary care hospital. Intervention: Comparison of cefepime, ceftazidime, ceftriaxone, cefotaxime and ciprofloxacin in the treatment of lower respiratory tract infections, urinary tract infections, skin/soft tissue infections, septicemia and febrile neutropenia. Main results: Cefepime treatment results in the lowest average cost per patient when used as initial empiric therapy for lower respiratory tract infections and for skin/soft tissue infections. Cefepime therapy is among the lowest cost treatments for the other infectious disease conditions and has the lowest cost for a weighted 'average' condition. Sensitivity analysis indicates that model results are most sensitive to duration of hospitalization. Conclusions: Initial empiric monotherapy with cefepime for serious infectious disease conditions may result in cost savings compared with alternative parenteral agents.",
keywords = "antibiotics, cefepime, costs, decision analysis, economic models",
author = "Michael Halpern and Brown, {Ruth E.} and Martine Drolet and Sorensen, {Sonja V.} and Mandell, {Lionel A.}",
year = "1997",
language = "English (US)",
volume = "8",
pages = "19--27",
journal = "Canadian Journal of Infectious Diseases and Medical Microbiology",
issn = "1712-9532",
publisher = "Pulsus Group Inc.",
number = "1",

}

TY - JOUR

T1 - Decision analysis modelling of costs and outcomes following cefepime monotherapy in Canada

AU - Halpern, Michael

AU - Brown, Ruth E.

AU - Drolet, Martine

AU - Sorensen, Sonja V.

AU - Mandell, Lionel A.

PY - 1997

Y1 - 1997

N2 - Objective: To evaluate the comparative cost of treatment and intermediate outcomes (percentage resistant organisms, days in hospital, etc) among cefepime and alternative parenteral antibiotics used for empiric monotherapy. Design: Decision analysis model, based on published literature, clinical trial results and information from infectious disease clinicians. Setting: A Canadian tertiary care hospital. Intervention: Comparison of cefepime, ceftazidime, ceftriaxone, cefotaxime and ciprofloxacin in the treatment of lower respiratory tract infections, urinary tract infections, skin/soft tissue infections, septicemia and febrile neutropenia. Main results: Cefepime treatment results in the lowest average cost per patient when used as initial empiric therapy for lower respiratory tract infections and for skin/soft tissue infections. Cefepime therapy is among the lowest cost treatments for the other infectious disease conditions and has the lowest cost for a weighted 'average' condition. Sensitivity analysis indicates that model results are most sensitive to duration of hospitalization. Conclusions: Initial empiric monotherapy with cefepime for serious infectious disease conditions may result in cost savings compared with alternative parenteral agents.

AB - Objective: To evaluate the comparative cost of treatment and intermediate outcomes (percentage resistant organisms, days in hospital, etc) among cefepime and alternative parenteral antibiotics used for empiric monotherapy. Design: Decision analysis model, based on published literature, clinical trial results and information from infectious disease clinicians. Setting: A Canadian tertiary care hospital. Intervention: Comparison of cefepime, ceftazidime, ceftriaxone, cefotaxime and ciprofloxacin in the treatment of lower respiratory tract infections, urinary tract infections, skin/soft tissue infections, septicemia and febrile neutropenia. Main results: Cefepime treatment results in the lowest average cost per patient when used as initial empiric therapy for lower respiratory tract infections and for skin/soft tissue infections. Cefepime therapy is among the lowest cost treatments for the other infectious disease conditions and has the lowest cost for a weighted 'average' condition. Sensitivity analysis indicates that model results are most sensitive to duration of hospitalization. Conclusions: Initial empiric monotherapy with cefepime for serious infectious disease conditions may result in cost savings compared with alternative parenteral agents.

KW - antibiotics

KW - cefepime

KW - costs

KW - decision analysis

KW - economic models

UR - http://www.scopus.com/inward/record.url?scp=0030911039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030911039&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 19

EP - 27

JO - Canadian Journal of Infectious Diseases and Medical Microbiology

JF - Canadian Journal of Infectious Diseases and Medical Microbiology

SN - 1712-9532

IS - 1

ER -